For Immediate Release
Cory Sullivan
(816)390-0645
News Archive
- 08.12.10 - Pre-Breeding Vaccinations Set the Stage for Improved Health
- 07.27.10 - Duramune Lyme Vaccine Approved for Use in Dogs
- 06.13.10 - Bovine Respiratory Disease Takes an Economic Toll on the Herd
- 06.07.10 - Management and Vaccination Keep Trichomoniasis at Bay
- 06.01.10 - Adding to the Bottom Line with Increased Cow Comfort
- 05.10.10 - Moreaux Presented BIVI Equine Leadership Award
- 05.05.10 - Test Herd, Then Treat to Avoid Parasite Resistance
- 04.05.10 - Strong Deworming Program Pays for Itself
- 11.23.09 - New Vetera West Nile Virus Vaccines
- 11.12.09 - PROZINC™ (protamine zinc recombinant human insulin) Receives FDA Approval
- 10.26.09 - Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business from Pfizer
- 10.01.09 - Mobile Dog Heart Health Tour Stopping in Central Park to Provide Free Heart Examinations
- 09.21.09 - BIVI Aquires Many of Fort Dodge's Products
- 08.17.09 - Midwest Mobile Dog Heart Health Tour to Provide Free Heart Examinations
- 08.09.09 - Boehringer Ingelheim Announces 2009 PRRS Research Award Recipients
- 08.05.09 - Swine Industry Call for PRRS Research Proposals
- 08.01.09 - BIVI Partners with EQUUS Foundation
- 05.28.09 - Swine Vets Complete Veterinary Program
- 04.27.09 - Joint Health Management Program Launched
- 03.16.09 - Mondaca Joins Swine Team
- 02.05.09 - BIVI Hires Brand Managers
- 08.11.08 - CircoFLEX-MycoFLEX Receives Approval
- 02.11.08 - Express Whole Herd Approved
- 05.02.07 - Baysinger Joins BIVI Swine Team
- 05.02.07 - Circovirus Receives Approval
- 04.08.07 - Express® FP 3 VL5 Announcement
- 04.08.07 - BIVI Recieves BVD PI Prevention Claim
News & Announcements
Boehringer Ingelheim Circovirus Vaccine Receives Four-Month Duration of Immunity Approval
According to Klaas Okkinga, marketing manager for Boehringer Ingelheim, the approved DOI label extension substantiates extensive research findings that Ingelvac CircoFLEX provides long-lasting protection from PCV2. “A vaccine that provides at least four months of PCV2 immunity is a significant benefit to producers in protecting pigs, both early and late, from damage caused by this disease,” says Okkinga.
“Currently, Ingelvac CircoFLEX is the only PCV2 vaccine available with proven DOI of this length when administered as a single-dose to pigs 3 weeks of age or older,” Okkinga adds. “Even when administered early, it still protects through the critical period in grow-finish, resulting in reduced pig mortality and improved performance.”
For more information on Ingelvac CircoFLEX vaccine for PCV2, as well as the diagnosis and management of PCVAD, contact Boehringer Ingelheim Vetmedica, Inc., at 800-325-9167
.
BI_Swine_PR_102306.pdfAbout Boehringer Ingelheim
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
About Boehringer Ingelheim Vetmedica, Inc.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
Visit www.bi-vetmedica.com for more information.